Stockscreener 앱 받기
5.76
0.17%
-0.010
시간 외 거래:
5.81
0.05
+0.87%
Savara Inc 주식(SVRA)의 최신 뉴스
The Bull Case For Savara (SVRA) Could Change Following Exclusive MOLBREEVI Distribution Deal With PANTHERx - simplywall.st
Will Savara Inc. stock outperform tech sector in 20252025 Price Momentum & Daily Price Action Insights - ulpravda.ru
How Savara Inc. (YB4P) stock compares with top peersProduct Launch & Technical Confirmation Alerts - ulpravda.ru
PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI - PharmiWeb.com
How Savara Inc. stock compares to growth peers2025 Institutional Moves & AI Optimized Trading Strategy Guides - ulpravda.ru
PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI* - Yahoo Finance
How Savara Inc. stock benefits from global expansionJuly 2025 Movers & Fast Gaining Stock Strategy Reports - ulpravda.ru
Will Savara Inc. (YB4P) stock rise with strong economyBuy Signal & Fast Exit Strategy with Risk Control - ulpravda.ru
Will Savara Inc. stock reach all time highs in 20252025 Market Sentiment & Safe Investment Capital Preservation Plans - ulpravda.ru
Aug Volume: How Savara Inc stock compares to growth peersRisk Management & Growth Focused Investment Plans - moha.gov.vn
Will Savara Inc. stock benefit from sector rotation2026 world cup usa national team group stage key players transition play expert forecast insights - ulpravda.ru
Oppenheimer Assumes Coverage of Savara (SVRA) With an Outperform Rating - MSN
FDA Clock Restarts: Savara Refiles MOLBREEVI for Rare Lung Disease - MyChesCo
Savara (NASDAQ:SVRA) Shares Down 5.1%Should You Sell? - MarketBeat
Savara Inc. (NASDAQ:SVRA) Short Interest Up 33.1% in December - MarketBeat
Death Cross: Is Savara Inc stock a defensive play in 2025Market Growth Summary & Safe Capital Growth Plans - moha.gov.vn
Savara Heads to JPMorgan Conference as Investors Watch Rare Lung Drug - MyChesCo
With 37% Ownership in Savara Inc. (NASDAQ:SVRA), Institutional Investors Have a Lot Riding on the Business - 富途牛牛
Swedbank AB Takes $1.96 Million Position in Savara Inc. $SVRA - MarketBeat
Gap Down: Is Savara Inc YB4P stock a buy for dividend portfolios2025 Trade Ideas & AI Based Buy and Sell Signals - moha.gov.vn
How Savara Inc. stock reacts to Fed rate cutsSector Performance Review & Your Free Entry to Smart Investing Starts Here - bollywoodhelpline.com
Savara price target raised to $10 from $8 at HC Wainwright - MSN
Savara Inc. ticks higher amid takeover speculation - MSN
Market Review: How MTEN stock performs in high volatility marketsMarket Trend Report & Accurate Intraday Trade Tips - moha.gov.vn
What is HC Wainwright's Forecast for Savara FY2027 Earnings? - MarketBeat
Savara (SVRA) Stock Price, Quote, News & History - Benzinga
FY2029 Earnings Estimate for Savara Issued By HC Wainwright - MarketBeat
SVRA SEC FilingsSavara Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Savara stock advances as Guggenheim reiterates Buy rating on BLA resubmission By Investing.com - Investing.com South Africa
Savara (SVRA) Receives Revised Buy Rating from HC Wainwright & C - GuruFocus
Savara stock price target raised to $10 from $8 at H.C. Wainwright By Investing.com - Investing.com Nigeria
Savara stock advances as Guggenheim reiterates Buy rating on BLA resubmission - Investing.com Nigeria
Savara stock price target raised to $10 from $8 at H.C. Wainwright - Investing.com Nigeria
How Investors May Respond To Savara (SVRA) Joining S&P Biotech Index After Key MOLBREEVI Patent Win - simplywall.st
Savara resubmits BLA for rare lung disease treatment with new manufacturer - Investing.com Nigeria
Savara (SVRA) Resubmits Molbreevi BLA to FDA for Autoimmune PAP Treatment - GuruFocus
Savara Resubmits Molbreevi Application to FDA for Rare Lung Disease - marketscreener.com
Savara Advances MOLBREEVI Toward Approval as Financing Boost Extends Cash Runway - MSN
Savara resubmits the Biologics License Application to the U.S. Food and Drug Administration for Molbreevi - marketscreener.com
Savara resubmits BLA for rare lung disease treatment with new manufacturer By Investing.com - Investing.com South Africa
Savara : Corporate Presentation - marketscreener.com
Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - Yahoo Finance
Savara Inc.(NasdaqGS: SVRA) added to S&P Biotechnology Select Industry Index - marketscreener.com
Savara Locks In Long-Term Europe Protection for Rare Lung Drug MOLBREEVI - MyChesCo
0.80%
4.56%
자본화:
|
볼륨(24시간):